Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-05

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study that is blinded to the patient and the investigator where the combination of Arfolitixorin + 5-FU is compared to Calciumfolinate + 5-FU. The patients will be randomised and will receive the above described combination as IV bolus injections, peroperatively in conjuction with collection of the first tissue sample.

A low dose (30 mg) and a high dose (120) mg of Arfolitixorin will be used in order to investigate the relation between dose of Arfolitixorin and TS-inhibition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

NCT00866944

Liver Metastases Colorectal Cancer

COMPLETED PHASE2

Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

NCT02244632

Colorectal Neoplasm

COMPLETED PHASE1/PHASE2

Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases

NCT01646554

Colorectal Cancer Metastatic Liver Metastases KRAS Mutated Colorectal Cancer

WITHDRAWN PHASE2/PHASE3

Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.

NCT01987102

Osteosarcoma

COMPLETED PHASE1/PHASE2

FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer

NCT04430985

Metastatic Colorectal Cancer

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Arfolitixorin (\[6R\] 5,10-methylenetetrahydrofolate) is a folate based biomodulator designed to replace leucovorin. Arfolitixorin is the key active metabolite of leucovorin (LV) and does in contrast to LV not require enzymatic metabolic activation. In clinical practice, LV is administered in the form of Calciumfolinate. A hypothesis is therefore that patients which are not capable of metabolizing LV could have a better antitumoral effect with Arfolitixorin administration. The antitumoural effect could be measured as inhibition of the enzyme thymidylate synthase, an enzyme essential for DNA synthesis.

Primary objective The primary objective is to compare the properties of Arfolitixorin and Calciumfolinate together with 5-fluorouracil (5-FU) on thymidylate synthase (TS) (i.e. measured as thymidylate synthase inhibition) in tumour and adjacent liver tissue in patients with liver metastases from colorectal cancer receiving a peroperative intravenous administration of Arfolitixorin or Calciumfolinate.

Secondary objectives To study safety in terms of adverse events and laboratory measurements; haematology and clinical chemistry.

To explore differences in pharmacokinetics of folates and folate metabolites in plasma.

To study gene expression in tumour and adjacent hepatic tissue and its correlation to tissue concentration.

To investigate the relation between the levels of deoxyuridine (dU) in plasma with the amount of TS inhibition in tumour tissue, in order to evaluate dU as a surrogate marker for TS-inhibition.

Study population:

Thirty adult patients with colorectal cancer and liver metastases, indicated for surgical removal will be randomised.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A total of 30 patients will be included in the study and will be equally randomised in three steps.

In the first phase, six patients will receive a reduced dose 5-FU; 250 mg / m², of which three patients will be randomized to additional Calciumfolinate and three patients will be randomized to additional Arfolitixorin. P When all six patients have been followed up in the context of visits consultation, a clinical safety evaluation (SE) of all AE, and SAE will be performed by two independent physicians If the responsible physicians finds that it is safe that the study will continue, we intend to increase the dose of 5-FU 500 mg / m, after which additional 12 patients will be included.

After inclusion of 6 patients receiving 5-FU 500 mg /m² in combination with Arfolitixorin in the dose of 30mg/m2 a dose adjustment will take place and the last 12 patients will be randomised to either Calciumfolinate 60 mg/m2 or Arfolitixorin 120 /m2.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Randomisation will be performed by a sealed envelope system. The randomisation envelopes are kept in a locked cabinet together with the randomisation list Two sets of code envelopes are prepared. The study personnel that will be responsible for study drug administration will have one set for the randomisation of patients and one set will be held by the investigator for emergency code breaking.

The code envelopes are prepared for each patient and contain information about what treatment the patient should receive. The randomisation will be made by the study personnel responsible for the administration of the study drugs at the day of the surgery. The patients will be randomised in consecutive order. The date and time of randomisation should be recorded on the document followed by a signature of the person opening the envelope.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arfolitixorin.

Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU

Group Type EXPERIMENTAL

Arfolitixorin

Intervention Type DRUG

Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate

Calciumfolinate.

Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU

Group Type ACTIVE_COMPARATOR

Arfolitixorin

Intervention Type DRUG

Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arfolitixorin

Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Calciumfolinate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must sign an informed consent document.
2. At least two liver metastases secondary to CRC. Patients must have removable metastases amenable to surgery.
3. Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG). Performance Status scale. (See Protocol Attachment 1.)
4. For women: Must be surgically sterile, postmenopausal, or compliant with a contraceptive regimen during and for 3 months after treatment. Fertile women must have a negative serum or urine pregnancy test (within 7 days before enrolment) and must not be lactating.
5. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 3 months after treatment.
6. Patient legally competent and able to communicate effectively with the study personnel as judged by the investigator.
7. Patient likely to co-operate during the study.
8. Patients must be at least 18 years of age.

Exclusion Criteria

Concurrent administration of any other anti-tumour therapy minimum 3 weeks before surgery according to clinical practise.

2\. Treatment within the last 30 days with a drug/device that has not received regulatory approval for any indication at the time of study entry.

3\. Any intake of medication, which could influence folate, and vitamin B12 status, within 30 days of surgery.

4\. Serious concomitant systemic disorders (e.g., active infection including HIV, cardiac disease) that in the opinion of the investigator would compromise the patient's ability to complete the study.

5\. Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.

6\. Patients with a high risk of postoperative liver failure due to advanced liver metastatic load.

7\. Pregnancy. 8. History of significant neurological or mental disorder, including seizures or dementia.

9\. Presence of clinically relevant (i.e., detectable by physical examination) third-space fluid collection (e.g., ascites, pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry.

10\. Known hypersensitivity to 5-FU and or Calciumfolinate/Arfolitixorin.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No